Precigen Inc PGEN

US Biotechnology

$7.75 ▲ +0.65% (+$0.05)

📈 Near 52W High ⬆️ Above Yest. High 🔥 High Short Interest

Open $8.08

Prev Close $7.70

Day Range $7.63 – $8.27

52W Range $2.99 – $8.04

Market Cap $2.77B

Beta 1.04

EPS (TTM) $-0.52

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2013-08-08
Shares Out.	356,510,000
Website	precigen.com/ ↗
Phone	13015569900
Employees	47
Revenue	$55.0M
Gross Profit	$52.2M
Net Income	$20.1M
Free Cash Flow	-$115.2M
Total Assets	$170.3M
Total Liabilities	$126.7M
Equity	$43.6M

About Precigen Inc

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Precigen Inc is a publicly traded company under the ticker symbol PGEN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.